Related Experiment Videos
Endothelial cell growth factor (ECGF) application to irradiated soft tissue
1Department of Otolaryngology-Head and Neck Surgery, University of Minnesota, Minneapolis 55455.
The Laryngoscope
|February 1, 1993
Summary
Endothelial cell growth factor (ECGF)-heparin significantly improved wound healing and vascularity in rabbit ear flaps, even after radiation. This suggests ECGF-heparin is a promising treatment for delayed wound healing in irradiated tissues.
Area of Science:
- Regenerative Medicine
- Wound Healing Research
- Tissue Engineering
Background:
- Delayed wound healing is a significant complication in cancer patients previously treated with radiation therapy.
- Endothelial cell growth factor (ECGF) has demonstrated potential in accelerating soft tissue neovascularization.
Purpose of the Study:
- To investigate the efficacy of an ECGF-heparin formulation in promoting neovascularization and viability in irradiated and nonirradiated rabbit ear skin flaps.
- To determine if prior radiation exposure affects the response to ECGF-heparin treatment.
Main Methods:
- An ECGF-heparin formulation (7200 µg/mL) in Gelfoam was applied to skin flaps in rabbits.
- Both previously irradiated (N=38) and nonirradiated (N=38) flaps were studied.
- Peripheral neovascularization and flap viability were quantified using polar planimetry and digital angiography.
Main Results:
- ECGF-heparin application resulted in a greater than twofold increase in vascularity and viability in both irradiated and nonirradiated flaps compared to controls (P < .01).
- The positive effects of ECGF-heparin on vascularization and viability were not significantly altered by previous radiation exposure.
Conclusions:
- ECGF-heparin demonstrates a significant angiogenic effect, enhancing vascularity and viability in surgical wounds.
- This formulation shows promise for improving outcomes in previously irradiated surgical sites, mitigating the challenges of delayed wound healing.